Background: There are no systemic therapies approved in the United States to treat pediatric psoriasis.
The overall annual incidence of psoriasis in children and adolescents in the United States (from birth to 18 years of age) was estimated to be 41 cases per 100,000 person-years during the period from 1970 through 1999, and the annual incidence increased during that time. 1 Approximately one third of adult patients with psoriasis report the development of psoriasis symptoms before adulthood. 2, 3 From 1979 through 2007, pediatric patients had approximately 3.8 million health care visits for their psoriasis, representing a considerable health care burden. 4 Comorbidities associated with pediatric psoriasis include metabolic syndrome, hypertension, hyperlipidemia, diabetes mellitus, rheumatoid arthritis, and Crohn's disease. 5, 6 Pediatric patients have impaired health-related quality of life (HRQOL) from their psoriasis, particularly with respect to emotional and school functioning. 7, 8 The cumulative life course impairment as a result of psoriasis, which affects the ability for individuals to fulfill their full lifetime potential, is particularly devastating for adolescents and young adults compared with patients who have adult-onset psoriasis. 9 Therapies currently approved by the US Food and Drug Administration (FDA) for the treatment of pediatric psoriasis in the United States include only a small number of topical agents with labeled indications limited to children 12 years of age or older. Of the interventions used for the treatment of moderate to severe plaque psoriasis in adults (phototherapy, methotrexate, cyclosporine, oral retinoids, or biologic agents) none is FDAapproved for children with moderate to severe psoriasis. Access to effective systemic treatments is limited for children and adolescents with psoriasis because of the lack of data and labeled indication. 10 Etanercept is a soluble tumor necrosis factor receptor fusion protein that reversibly binds to tumor necrosis factor. Etanercept is approved for the treatment of adults with moderately to severely active rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis, and moderate to severe plaque psoriasis. Etanercept has also been approved since 1999 in the United States to treat children with moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) down to 2 years of age. 11 Etanercept has been shown to be effective for the treatment of JIA at 0.8 mg/kg once weekly (maximum 50 mg) with a favorable safety profile during long-term therapy. 12, 13 We now report 5-year results from an open-label extension (OLE) study to examine the safety and efficacy of etanercept (0.8 mg/kg) for treating moderate to severe plaque psoriasis in pediatric patients enrolled at 4 to 17 years of age.
METHODS

Study design
This study (study 20050111) was an OLE of the parent 20030211 study (ClinicalTrials.gov no. NCT00078819), a 48-week study that enrolled 211 patients with moderate to severe plaque psoriasis between 4 and 17 years of age. 14 Patients were allowed to discontinue etanercept from week 96 if they had a static physician global assessment (sPGA) status of clear/almost clear (score of 0/1), and could restart etanercept at the discretion of the investigator. An interim analysis at week 96 has been reported. 15 Patients who enrolled in the OLE study were followed up through week 264 or until they turned 18 years of age, whichever came last.
The study was conducted in accordance with International Conference on Harmonization Good Clinical Practice regulations and guidelines and with the Declaration of Helsinki. Institutional review boards at each participating site approved the study protocol and amendments, and written informed consent was provided by parents or legal guardians of each patient before initiation of study-related procedures. This study was registered under ClinicalTrials.gov no. NCT00141921 on August 31, 2005, and the first patient was enrolled on August 11, 2005 . This analysis includes data through February 22, 2012. This open-label, 264-week extension study showed no unexpected adverse events and efficacy was maintained. d Etanercept could be an option for pediatric psoriasis; access is limited by lack of disease-specific labeling.
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Patients
Children and adolescents with moderate to severe plaque psoriasis who completed study 20030211 or who had not completed the parent study but had achieved substantial benefit from etanercept on or after week 12 with no serious adverse event (SAE) or other clinically significant adverse event (AE) considered related to etanercept were eligible to participate in the OLE study. Substantial benefit in the parent study was defined as achieving a 50% or greater improvement from baseline in Psoriasis Area and Severity Index (PASI) score.
End points
The primary end point was the incidence of AEs and SAEs, including infectious events. A SAE was defined as an event that resulted in persistent or significant disability or incapacity or death, was life threatening, required hospitalization, or was a congenital anomaly or birth defect. Additional key safety end points included the incidence of antinuclear antibody and anti-etanercept antibody formation. The key efficacy end points included the incidence of 75% improvement in PASI score (PASI 75) and 90% improvement in PASI score (PASI 90) from baseline of the parent study and patients achieving clear/almost clear (score 0/1) on the sPGA.
Statistical considerations
Patients who received 1 or more doses of etanercept in the extension study were included in all safety and efficacy analyses. An analysis of growth (height, weight, and body mass index percentile based on growth charts from the Centers for Disease Control and Prevention [CDC] 16 ) was performed on the subset of patients who stayed in the study through year 5 and did not reach 20 years of age (the maximum age in the CDC growth charts). No imputation was used for missing data.
RESULTS
Patients
Of 211 patients enrolled in the parent study, 14 182 patients enrolled in the OLE study, 181 received etanercept, 140 completed 96 weeks, 15 and 69 patients completed 264 weeks on study. Of these 69 patients, 28 continued further follow-up past week 264 until they reached 18 years of age ( Fig 1) . There were 621.0 patient-years of exposure to etanercept during the OLE study. Baseline demographics have been previously reported 15 ; briefly, the mean (SD) age was 12.8 (3.5) years, 51% were male, and 76% were white. Mean psoriasisaffected body surface area, PASI scores, and sPGA scores were improved at the entry into the OLE study compared with the baseline of the parent study (Table I) . Only 5 patients elected to discontinue etanercept after week 96 because they were rated as clear/almost clear (score 0/1) on the sPGA and 3 of static physician global assessment J AM ACAD DERMATOL these patients reinstated treatment later. The most common reasons for discontinuing from the OLE study were consent withdrawn (n = 42), loss to follow-up (n = 19), and noncompliance (n = 17) (Fig 1) . Of the 42 patients who withdrew consent, 16 provided a reason: approximately half withdrew for reasons of inconsistent results or decline in efficacy and the others were unable or did not want to continue study visits because of relocation, travel burden, or they wanted to take a medication break. For the subset of 43 patients who remained on the study through year 5 and did not turn 20 years of age (because CDC percentile data were only available up to age 20 years), mean percentiles for height, weight, and body mass index were above the 50th percentile and remained relatively constant throughout the study (Table II) . Results for all patients showed a similar trend (data not shown).
Safety
A total of 161 (89.0%) patients reported an AE through week 264. The most commonly reported AEs were upper respiratory tract infection (37.6%), nasopharyngitis (26.0%), and headache (21.5%) (Table III) . Injection-site reactions were reported by 16 (8.8%) patients. Through week 264, 7 patients reported 8 SAEs (Table IV) including 2 patients with infectious events (cellulitis and infectious mononucleosis). Four events were reported before week 96, 15 and 4 (cellulitis, infectious mononucleosis, osteonecrosis, and thyroid cyst) were reported during the subsequent 168 weeks. Only 1 SAE (cellulitis) was considered by the investigator to be related to the investigational product. Six patients withdrew from the study between weeks 96 and 264 because of the following AEs (none was a SAE): Crohn's disease (n = 2), glomerulonephritis (n = 1), psoriasis worsening (n = 1), sinusitis (n = 1), and VIIth nerve paralysis (n = 1). Fig 2; available at http://www.jaad. org). Similarly, the mean age of patients with antietanercept antibodies was similar to the overall population (data not shown). Antinuclear antibody was detected in 11 (6%) patients at baseline, 0 patients at week 48, 3 (2%) at week 96, 5 (3%) at week 144, 6 (3%) at week 168, and 2 (1%) at week 264.
Efficacy
Efficacy outcomes of PASI score responses and sPGA scores through week 96 have been previously reported. 14, 15 The percentages of patients achieving PASI 75 and PASI 90 responses from baseline in the parent study remained relatively constant at approximately 60% to 70% and 30% to 40%, respectively, at week 96 through week 264 (Fig 2, A and B) . Similarly, the percentage of patients who achieved sPGA status of clear/almost clear (score 0/1) remained relatively constant at approximately 40% to 50% from week 96 through week 264 (Fig 2, C ) . Rates of PASI 75 responses were slightly lower in patients categorized as obese or overweight compared with patients at healthy weight ( Supplemental Fig 3; available at http://www.jaad.org).
DISCUSSION
To our knowledge, this was the largest published study with the longest follow-up of any biologic therapy in pediatric patients with psoriasis. 10 The retention in efficacy over 5 years in these patients was particularly encouraging, as the growing children were restricted to a maximum dose of 50 mg weekly regardless of body mass index. Obesity appears to be a risk factor for psoriasis in children and adolescents, [17] [18] [19] and higher weight is associated with greater severity of disease. 19 These J AM ACAD DERMATOL VOLUME 74, NUMBER 2 results suggest that etanercept could provide a therapeutic option for this patient population. Etanercept has been approved for the treatment of JIA in children and adolescents for approximately 15 years, and although that patient population is clinically different from patients with psoriasis, the safety profile of etanercept is similar in both populations. In general, the use of tumor necrosis factor blockers is associated with increased rates of infection in both adult and pediatric patients. 20 In the original randomized, controlled clinical study to evaluate the safety and efficacy of etanercept in children with JIA, the most common AEs were injection-site reactions (39%), upper respiratory tract infections (35%), and headache (20%). During that study and in the following 8 years of follow-up in the subsequent OLE study, 9 medically important infections were reported for a rate of 0.03 events per patient-year. [21] [22] [23] Importantly, rates of medically important infections did not increase with increased exposure to etanercept. 23 Recent safety data from registries 24, 25 and prospective studies 26, 27 of patients with JIA also note an increased risk of infections, which are usually mild in severity.
The long-term efficacy of etanercept for patients with psoriasis appears to be consistent between pediatric and adult populations. PASI 75 responses were achieved and maintained in approximately 60% of the children and adolescents who remained on etanercept for up to 5 years in our study. This result is similar to the rate of PASI 75 responses reported in adults receiving etanercept at a stable dose of 50 mg weekly for up to 72 weeks. 28 The rate of sPGA responses of clear/almost clear at week 96 was approximately 50%, which was higher than the rate from a pooled analysis of long-term data in adults with psoriasis (;30%) who received etanercept for up to 48 months. 29 Rates of PASI and sPGA responses appear to be relatively stable with long-term treatment with etanercept in both pediatric and adult patients with psoriasis.
A limitation of the study was the relatively small number of patients in the study overall and in the number of patients who remained on etanercept through the OLE study. Rare safety events that may only occur in children and adolescents would be unlikely to be observed with so few patient-years of exposure. In addition, as patients had strict eligibility requirements for entry into the parent study, these results are not generalizable to the overall population of pediatric patients with psoriasis.
Effective treatment for moderate to severe psoriasis is important for all patients. The stigmatizing effect of psoriasis may especially impact young patients who have not developed coping skills to deal with their disease. 9 Moreover, major life decisions occur during adolescence and early adulthood, including the choices of careers, marriage, and childbearing; impairments influencing these decisions affect an individual's cumulative life course and are largely irreversible. 9 Children and adolescents require early effective treatment to minimize the negative effects of psoriasis. Etanercept has been shown to improve HRQOL in the pediatric population included in this study with both short-term 14 and long-term 15 treatment. Although HRQOL measures used in clinical trials do not provide data on cumulative life course impairment, they do provide a snapshot of the patient's perspective on their HRQOL.
In conclusion, etanercept provided clinical benefit for up to 264 weeks in children and adolescents with moderate to severe plaque psoriasis. No new safety concerns were observed with long-term treatment in this patient population.
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